GlycoNex is advancing a new generation of glycan-directed antibody-drug conjugates (ADCs) aimed at improving precision in solid tumor treatment. While many ADCs target well-known protein markers, GlycoNex focuses on tumor-associated glycans, carbohydrate structures overexpressed on cancer cells but largely absent...
Linda Pullan, Ph.D., of Pullan Consulting, has been working with biopharma business development executives for more than two decades, offering her expertise to help companies find and negotiate deals, from evaluations to research collaborations to licenses to co-development, and acquisitions....
Medication nonadherence is one of the most persistent challenges in modern healthcare, driving up costs and compromising outcomes across chronic disease categories. Enter Adhere+, a SaaS-based platform that enables providers to monitor and support patients’ care plan adherence through the...
Elysium Therapeutics is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, such as fentanyl. In this installment of Bench2Bedside, Elysium’s CEO Greg Sturmer discusses the need for improved rescue medicines...
Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. In this installment of Bench2Bedside, CEO Francisco Salva discusses the company’s two lead programs, ATR-12 and ATR-04, developed from a proprietary platform of engineered...
Cyrano Therapeutics is a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss. In this installment of Bench2Bedside, President and CEO Rick Geoffrion discusses his company, development plans, and why he believes CYR-064 has the potential to...